Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Wilms Tumor 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioma 2Ependymoma 2Xanthogranuloma, Juvenile 1Lymphoma 1Histiocytic Sarcoma 1Central Nervous System Neoplasms 1

Interventions

Cyclophosphamide 62Vincristine 45Doxorubicin 43Etoposide 42Rituximab 37Prednisone 31Filgrastim 31Biopsy 27Peripheral Blood Stem Cell Transplantation 25Cytarabine 24Radiotherapy 22fludarabine phosphate 19Specimen Handling 19Methotrexate 19Magnetic Resonance Spectroscopy 18Prednisolone 17Melphalan 16Ifosfamide 14Dexamethasone 14Bleomycin 13Leucovorin 12Cyclosporine 12Carmustine 12sargramostim 11Cisplatin 10Vinblastine 8Chlorambucil 8Busulfan 8fludarabine 7Nivolumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma × selpercatinib × Clear all
NCT04320888 2026-05-27

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
1 enrolled 3 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡